4/4
08:17 am
imnm
Immunome to Present at the 24th Annual Needham Virtual Healthcare Conference [Yahoo! Finance]
Low
Report
Immunome to Present at the 24th Annual Needham Virtual Healthcare Conference [Yahoo! Finance]
4/4
08:00 am
imnm
Immunome to Present at the 24th Annual Needham Virtual Healthcare Conference
Medium
Report
Immunome to Present at the 24th Annual Needham Virtual Healthcare Conference
4/3
04:05 pm
imnm
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Medium
Report
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
4/2
08:31 am
imnm
Immunome, Inc. (NASDAQ: IMNM) is now covered by analysts at Lake Street Capital. They set a "buy" rating and a $23.00 price target on the stock.
Medium
Report
Immunome, Inc. (NASDAQ: IMNM) is now covered by analysts at Lake Street Capital. They set a "buy" rating and a $23.00 price target on the stock.
3/26
04:12 pm
imnm
Zentalis Pharmaceuticals Reports Full Year 2024 Financial Results and Operational Updates [Yahoo! Finance]
Medium
Report
Zentalis Pharmaceuticals Reports Full Year 2024 Financial Results and Operational Updates [Yahoo! Finance]
3/20
11:06 am
imnm
Immunome, Inc. (NASDAQ: IMNM) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $33.00 price target on the stock.
Low
Report
Immunome, Inc. (NASDAQ: IMNM) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $33.00 price target on the stock.
3/20
09:58 am
imnm
Immunome, Inc. (NASDAQ: IMNM) had its "overweight" rating re-affirmed by analysts at Stephens. They now have a $30.00 price target on the stock.
Low
Report
Immunome, Inc. (NASDAQ: IMNM) had its "overweight" rating re-affirmed by analysts at Stephens. They now have a $30.00 price target on the stock.
3/20
09:37 am
imnm
Immunome, Inc. (NASDAQ: IMNM) had its price target lowered by analysts at Guggenheim from $35.00 to $25.00. They now have a "buy" rating on the stock.
Low
Report
Immunome, Inc. (NASDAQ: IMNM) had its price target lowered by analysts at Guggenheim from $35.00 to $25.00. They now have a "buy" rating on the stock.
3/19
04:05 pm
imnm
Immunome Reports Full Year 2024 Financial Results and Provides Business Update
Low
Report
Immunome Reports Full Year 2024 Financial Results and Provides Business Update
3/11
08:56 am
imnm
Immunome, Inc. (NASDAQ: IMNM) is now covered by analysts at Lifesci Capital. They set an "outperform" rating and a $20.00 price target on the stock.
Medium
Report
Immunome, Inc. (NASDAQ: IMNM) is now covered by analysts at Lifesci Capital. They set an "outperform" rating and a $20.00 price target on the stock.
3/10
12:14 pm
imnm
Immunome, Inc. (NASDAQ: IMNM) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $33.00 price target on the stock.
Low
Report
Immunome, Inc. (NASDAQ: IMNM) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $33.00 price target on the stock.
3/10
07:59 am
imnm
Immunome Doses First Patient in Phase 1 Trial of IM-1021, a ROR1-Targeted ADC [Yahoo! Finance]
Medium
Report
Immunome Doses First Patient in Phase 1 Trial of IM-1021, a ROR1-Targeted ADC [Yahoo! Finance]
3/10
07:41 am
imnm
Immunome Doses First Patient in Phase 1 Trial of IM-1021, a ROR1-Targeted ADC
Medium
Report
Immunome Doses First Patient in Phase 1 Trial of IM-1021, a ROR1-Targeted ADC
3/6
04:01 pm
imnm
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Low
Report
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2/25
08:16 am
imnm
Immunome to Present at Upcoming March Conferences [Yahoo! Finance]
Low
Report
Immunome to Present at Upcoming March Conferences [Yahoo! Finance]
2/25
08:00 am
imnm
Immunome to Present at Upcoming March Conferences
Low
Report
Immunome to Present at Upcoming March Conferences
2/11
09:00 am
imnm
Aro Biotherapeutics Announces Leadership Transition and Appoints Purnanand Sarma, Ph.D., as Chief Executive Officer [Yahoo! Finance]
Medium
Report
Aro Biotherapeutics Announces Leadership Transition and Appoints Purnanand Sarma, Ph.D., as Chief Executive Officer [Yahoo! Finance]
2/11
08:30 am
imnm
Aro Biotherapeutics Announces Leadership Transition and Appoints Purnanand Sarma, Ph.D., as Chief Executive Officer
High
Report
Aro Biotherapeutics Announces Leadership Transition and Appoints Purnanand Sarma, Ph.D., as Chief Executive Officer
2/6
04:01 pm
imnm
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Medium
Report
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
1/31
04:21 pm
imnm
Immunome Announces Closing of Upsized Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares [Yahoo! Finance]
Medium
Report
Immunome Announces Closing of Upsized Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares [Yahoo! Finance]
1/31
04:01 pm
imnm
Immunome Announces Closing of Upsized Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
Medium
Report
Immunome Announces Closing of Upsized Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
1/30
01:47 am
imnm
https://seekingalpha.com/news/4400498-immunome-raises-150m-in-upsized-offering [Seeking Alpha]
High
Report
https://seekingalpha.com/news/4400498-immunome-raises-150m-in-upsized-offering [Seeking Alpha]
1/29
11:11 pm
imnm
Immunome Announces Pricing of Upsized Public Offering of Common Stock
High
Report
Immunome Announces Pricing of Upsized Public Offering of Common Stock
1/29
04:27 pm
imnm
Immunome Announces Proposed Public Offering of Common Stock
High
Report
Immunome Announces Proposed Public Offering of Common Stock
1/13
06:17 pm
imnm
Immunome, Inc. (NASDAQ: IMNM) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $33.00 price target on the stock.
Medium
Report
Immunome, Inc. (NASDAQ: IMNM) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $33.00 price target on the stock.